Clinical Trial Update: A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating BBI608 plus weekly paclitaxel for gastric and gastroesophageal junction cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• BBI608
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-05-10